INTRODUCTION
The reaction catalysed by carnitine palmitoyltransferase (CPT)-I is a rate-controlling step in the pathway of long-chain fatty acid β-oxidation [1] . CPT-I is located on the mitochondrial outer membrane and catalyses the conversion of acyl-CoA to acylcarnitine. The acylcarnitine molecule is transported into the mitochondria by the carnitine acylcarnitine translocase in exchange for carnitine. CPT-II is located on the mitochondrial inner membrane and reverses the reaction of CPT-I to regenerate acyl-CoA from acylcarnitine.
Two isoforms of CPT-I have been cloned [2, 3] . The ' liver ' isoform (CPT-Iα) is expressed in most tissues, including liver, kidney, lung and heart [4] . The ' muscle ' isoform (CPT-Iβ) is expressed in the heart, skeletal muscle and adipose tissue [2] . CPT-Iα is not expressed in skeletal muscle or brown adipose tissue [1] . In the heart, CPT-Iα is the main isoform expressed before birth, whereas CPT-Iβ is the predominant isoform in the adult heart [5] . Although these isoforms of CPT-I catalyse the same reaction, they have slightly different properties. Both isoforms are inhibited by malonyl-CoA, which is a precursor for fatty-acid synthesis [6] . CPT-Iβ is inherently more sensitive to malonyl-CoA than CPT-Iα. However, the sensitivity of CPT-Iα to malonyl-CoA inhibition is increased by insulin but the sensitivity of CPT-Iβ is not altered [6] .
Expression of the CPT-Iα gene is regulated by developmental, dietary and hormonal factors. The CPT-Iα gene is not expressed in the liver before birth and expression rises following birth [7] . CPT-Iα expression is elevated in starved rats or in rats on high Abbreviations used : CPT, carnitine palmitoyltransferase ; NF-Y, nuclear factor Y ; FISH, fluorescence in situ hybridization ; CRE, cAMP-responsive element ; C/EBP, CCAAT-enhancer binding protein ; SV, simian virus. 1 To whom correspondence should be addressed (e-mail EPARK!UTMEM1.UTMEM.EDU).
The nucleotide sequence data for the promoter of the CPT-Iα gene has been submitted to GenBank with accession number AF020776. Key words : fatty acid transport, hepatic genes, transcriptional regulation.
fat diets [6, 7] . In addition to dietary regulation, CPT-Iα transcription is elevated in hyperthyroid animals and streptozotocintreated diabetic rats [6, 8, 9] . Long-chain fatty acids and lipidlowering agents such as clofibrate enhance transcription of the CPT-Iα gene [10] . These observations indicate a prominent role for thyroid hormone, fatty acids and insulin in regulating CPT-Iα expression.
To further analyse the mechanisms by which CPT-Iα expression is regulated, we cloned the CPT-Iα promoter from a rat genomic library [4] . The CPT-Iα gene contains two exons before the exon containing the initiating methionine codon [3, 4] . Examination of the sequence of the proximal promoter suggested that the CPT-Iα gene has a TATA-less promoter. In the present work, characterization of the proximal promoter of the CPT-Iα gene is reported. A region spanning 200 nt in the CPT-Iα promoter is responsible for the regulation of basal gene expression. The transcription factors Sp1, Sp3 and nuclear factor Y (NF-Y) bind to sites in the CPT proximal promoter and stimulate transcription. Other binding sites for nuclear proteins were also identified. Our studies demonstrate that CPT-Iα is a TATA-less gene and provide a foundation for further analysis of the regulation of CPT-Iα expression.
EXPERIMENTAL Fluorescence in situ hybridization (FISH)
Fibroblasts from neonatal rats were cultured and harvested following conventional cytogenic procedures and air-dried slides were made for FISH analysis. The fibroblasts were denatured for 2 min in 70 % (w\v) formamide\2iSSC (1iSSC l 0.15 M NaCl\0.015 M sodium citrate) at 70 mC and dehydrated in ethanol. A plasmid clone containing a 10 kb insert of the CPT-Iα gene was labelled with digoxigenin dUTP (BoehringerMannheim) by nick translation and used as a probe for FISH. Hybridization conditions were described previously [11] . Hybridization signals were detected with anti-digoxigenin-horseradish peroxidase (Boehringer-Mannheim), cyanine-3 tryamide (NEN Life Science Products, Boston, MA, U.S.A.), and the chromosomes were counterstained with 0.4 ug\ml of DAPI (Sigma) in an anti-fade buffer. The preparations were viewed with an Olympus BX60 epifluorescence microscope and photographed.
DNase-I-footprint analysis
DNase-I footprint probes were prepared by PCR amplification of a region in the CPT-Iα promoter. Forward primer : 5h-CACTCGAGCAGCCAAACAACCTAAAGT-3h, and reverse primer : 5h-TGGGATCCCGAGTCTGTGGACGGCGGCG-3h were used to generate a fragment from nt k383 to j27. The PCR fragment was cloned into the XhoI and BamHI sites of pBluescript II K\S +/− . The CPT-Iα-pBS vector was digested with BamHI to generate a probe labelled on the top strand or with XhoI to label the bottom strand. The resulting overhang was treated with alkaline phosphatase and labelled with [γ-$#P]ATP and T4 polynucleotide kinase. After digestion with the second restriction enzyme, the probe was purified from a 1 % (w\v) agarose gel.
Proteins were isolated from rat liver nuclei as described by Gorski et al. [12] . The radiolabelled probes were incubated with rat liver nuclear proteins and treated with DNase I as described by Park et al. [13] . The reactions were resolved on a denaturing (5 % w\v) acrylamide gel in 1iTBE (89 mM Tris\89 mM borate\2 mM EDTA) running buffer.
Electrophoretic mobility-shift assays
Probes for gel-shift assays were created by labelling double stranded oligonucleotides with Klenow enzyme and [α-$#P]dCTP [14] . The upstream Sp1 site will be referred to as Sp1(F2) and the downstream Sp1 site as Sp1(F1). The oligonucleotides corresponded to protein binding sites in the CPT-Iα promoter as follows : Sp1(F1), 5h-CTAGAGCCTCGCCCGCCCCTGCTT-3h; Sp1(F2), 5h-CTAGACAGGCCCCGCCCCGTCCTT-3h ; CCAAT box, 5h-CTAGAGCTCAGCCAATCCCCGT-3h ; region I, 5h-CTAGACCGGCTGGGCTCAGCCAT-3h ; region II, 5h-CTAGATCTTTACTGAACTCCT-3h ; region III, 5h-CTAGACTAGGTCTGTAGTTCACAAGCTCGGT-3h. Mutated oligonucleotides of these protein-binding regions were generated as follows (the mutated nucleotides are underlined) : Sp1(F1) Mut, 5h-CTAGAGCCTCGCATGCATCTGCTT-3h ; CCAAT box Mut, 5h-CTAGAGCTCAGCTGGCCACCCGT3h ; region I Mut, 5h-CTAGACCGGCGAATTCCAGCCAT-3h ; region II Mut, 5h-CTAGATCTCAGTACGACTCCT-3h ; region III(1) Mut, 5h-CTAGACTGAACGATTAGTTCACAAGCTC-GGT-3h ; region III(2) Mut, 5h-CTAGACTAGGTCTGTAG-ACATGGTGCTCGGT-3h. Oligomers for the Sp1 and cAMPresponsive-element (CRE) consensus sites contain the following sequences : Sp1, 5h-ATTCGATCGGGGCGGGGCGAGC-3h and CRE, 5h-CCCCTTACGTCAGAGG-3h.
The labelled probe (30 000 c.p.m.) was combined with proteins isolated from rat liver nuclei in 25 mM Tris\HCl, pH 7.4\80 mM KCl\0.1 mM EDTA\1 mM dithiothreitol and 10 % (v\v) glycerol [15] . The non-specific competitor added to each binding reaction was either 
Construction of luciferase vectors
Nucleotides from k1653 in the promoter to j64 in exon 2, including the first intron, were removed from the original P1 clone by EcoRI-SalI digestion. This fragment (k1653\j64 CPT-Iα) was ligated into the pGL3 basic luciferase vector (Promega). The k1653\j19 CPT-Iα-Luc vector was prepared by digesting k1653\j64 CPT-Iα-Luc with BssHI-BglII and removing the first intron. A 70-bp double-stranded oligomer from nt k52 to j19 of the CPT-Iα gene, with appropriate overhangs, was ligated into the BssHII-BglII sites. The additional 5h region of the promoter (nt k6839\k1653) was initially isolated from the P1 clone and inserted into the multiple cloning site of pBluescript K\S +/− at SalI-EcoRI. The upstream promoter region was then removed from pBS by a KpnI-EcoRI digest and ligated into the k1653\j19 CPT-Iα-Luc vector, resulting in k6839\j19 CPT-Iα-Luc. The k4495\j19 CPT-Iα-Luc vector was created by ligating k6839\j19 CPT-Iα-Luc, which was digested at XhoI sites in the multiple cloning site and at nucleotide k4495.
Serial deletions from the 5h end of k1653\j19 CPT-Iα-Luc were created with the Erase a Base kit (Promega). The k1653\j19 CPT-Iα-Luc vector was digested with SpeI and filled in with α-phosphorothioate dNTPs. Exonuclease III digestion began from an EcoRI overhang at nt k1653 and aliquots were collected at various times from a 30 mC incubation mixture. CPT-Iα-Luc vectors were generated through ligation of the serial deletion constructs. A k52\j19 CPT-Iα-Luc vector was constructed by ligating an EcoRI-BssHII k1653\j19 CPT-Luc digest. The k965\j19 and k193\j19 CPT-Iα-Luc vectors were prepared as described previously [4] .
Site-directed mutagenesis was conducted using the pALTER system (Promega). The DpnI QuickChange method (Stratagene, La Jolla, CA, U.S.A.) was used to generate mutations in footprinted region III. The k1653\j19 region of the promoter was ligated into the pALTER vector using the KpnI and HindIII sites. Phosphorylated oligonucleotides were generated based on the mutations made in the gel-shift oligomers that disrupted protein binding at specific sites in the promoter, and are given below : Sp1(F1) Mut, 5h-GCCTAGCCTCGCATGCATCTGC-TCGGACTC-3h ; Sp1(F2) Mut, 5h-CCTGGTCCAGGCCAT GCATCGTCCT GCCCGC-3h ; NF-Y Mut, 5h-GGCTGGGCT-CAGCTGGCCACCCGCGGCGC-3h ; region I Mut, 5h-TCC-TGCCCGCGCCGCAGCCCGGCGAATTCCAGCCAATCA-CCCGCGGCG-3h ; region II Mut, 5h-GGGTCCTAGCC-TCAGTTTCTCAGTACTACTCCTCCCCGCAGCCCCG-3h ; region III Mut, 5h-TAAGGAATGCTGTCCTAGGTCTGTA-GCCATGGTGCTCGGGTCCTAGCCTCAGTTTCTTTA-3h.
Mutations introduced into the CPT-Iα promoter were confirmed by sequence analysis. The mutated k1653\j19 CPT-Iα fragments were removed from pALTER-1 and ligated into the KpnI and BglII sites of the pGL3-basic-luciferase vector. The mutation of the most 5h Sp1 site was removed from the CPT-Nuclear factor Y and Sp1 regulate CPT-Iα gene expression 
Cell culture, transfections and luciferase assays
Transient transfections were conducted in HepG2 cells using calcium phosphate precipitation as described previously [16] . The calcium phosphate precipitate contained equimolar concentrations of CPT-Iα-Luc vector and 1 µg of simian virus (SV)40-β-galactosidase as a transfection control. Sufficient pBluescript was added for a final concentration of 4 µg of DNA per plate to account for the variation in sizes of the CPT-Iα-Luc vectors. HepG2 cells were maintained in Dulbecco's modified Eagle's medium containing 5 % (v\v) fetal-bovine serum and 5 % (v\v) calf serum. Cells were treated with trypsin and replated at 60k70 % confluence. After 4 h, to allow cell reattachment, the calcium phosphate-DNA precipitate was added to each plate and incubated overnight. The cells were washed twice with PBS and incubated for 24 h in serum-free medium.
Luciferase activity was measured as described previously [4] . Transiently transfected HepG2 cells were harvested in reporter lysis buffer (Promega). Cells were subjected to one round of freeze-thawing to enhance lysis. The lysed cells were centrifuged to remove cell debris and the supernatant was collected. Luciferase assays were conducted with 10 µl of cell extract and 100 µl of luciferase assay reagent (Promega) and luciferase activity was measured in a TD 20\20 luminometer. β-Galactosidase activity was determined with 200 µl of cell extract and O-nitrophenyl-β--galactopyranoside in a colorimetric assay [4] . The protein concentration of the cell lysate was measured using the Bio-Rad protein assay reagent (Bio-Rad). Luciferase data are expressed as luciferase activity corrected for β-galactosidase activity and for protein concentration in the cell lysate. Each transfection was conducted in duplicate and repeated four to six times.
Expression of site-directed mutant CPT-Iα-Luc vectors was analysed using the dual-luciferase reporter assay system (Promega). Transient transfections of HepG2 cells were conducted as described above but included the co-transfection of pRL-cytomegalovirus Renilla. The Renilla luciferase activity replaced β-galactosidase activity as the transfection control.
Sequencing
DNA was sequenced with the Dye terminator cycle sequencing system (Perkin-Elmer) and analysed at the Molecular Resource Center of the University of Tennessee.
RESULTS AND DISCUSSION
The goals of this study were to identify promoter elements and trans-acting factors that regulate expression of the CPT-Iα gene. Previously, we had reported the cloning of the CPT-Iα promoter from nt k965 to k1 [4] . To further characterize the CPT-Iα gene, we first cloned and sequenced the upstream promoter region from nt k6839 to k965 (results not shown). Secondly, the chromosomal location of the rat CPT-Iα gene was determined ( Figure 1 ). Complete metaphase spreads of rat chromosomes were examined and consistent fluorescent signals were observed on chromosome 1 in the q43 region. The human CPT-Iα gene maps to chromosome 11q13-ter [17, 18] and this region is syntentic with the rat 1q4 [19] . The human CPT-Iβ gene is found on chromosome 22q13.3 [18, 20] , and the rat CPT-Iβ gene maps to the syntentic region on chromosome 7q34 [11, 19] . These data show that, like their human counterparts, rat CPT-Iα and CPT-Iβ genes are present at different chromosomal loci.
The next experiments were designed to identify regions in the CPT-Iα promoter that controlled basal expression of the CPT-Iα gene. A series of serial deletions from the 5h end of the CPT-Iα promoter were constructed and ligated to the luciferase reporter gene. These deletions were created using exonuclease III digestion from the 5h end of the k1653\j19 CPT-Iα promoter fragment. Approx. 200 bp were removed from the 5h end of each deletion. Two longer CPT-Iα-Luc constructs (k6839\j19 and k4495\j19) were created to evaluate the contribution of the entire promoter to transcriptional activity. These CPT-Iα-Luc constructs were transiently transfected into HepG2 cells and luciferase assays were performed. Luciferase activity for each serial deletion was compared with the activity of the full length k1653\j19 CPT-Iα -Luc vector, which was given a relative value of 100 % (Figure 2 ). The k1653\j19 CPT-Iα-Luc vector was chosen as the baseline because the site-directed mutagenesis of specific promoter elements was conducted in this vector.
The longer promoter regions drove expression of the luciferase reporter gene with a similar efficiency to the k1653\j19 promoter fragment (Figure 2) . The relative activity of the k6839\j19 vector was 70p13 % and that of the k4495\j19 vector was 123p25 % of that of the k1653\j19 vector. A modest increase in basal expression was observed with progressive deletion of the CPT-Iα promoter beyond the k1653 point. This 2-fold increase in luciferase activity was constant for the shorter constructs until there was truncation beyond the k193 nucleotide. The k193\j19 CPT-Iα-Luc construct had a relative activity of 230p30 %, whereas the relative activity of the k52\j19 CPT-Iα-Luc construct was 7p2 %. Based on these data, the sequences between nt k193 and k52 had a major influence on the basal activity of the CPT-Iα promoter. Therefore the remaining experiments focused on characterizing this region of the promoter.
To identify potential transcription factor binding sites, DNase I footprint analysis of the proximal promoter region was
Figure 2 Identification of regions in the CPT-Iα promoter that regulate basal expression
Serial deletions of the k6839/j19 CPT-Iα (CPT) promoter were ligated to the luciferase (Luc) reporter gene. HepG2 cells were transiently transfected with 3.0 µg of CPT-Iα-Luc and 1.0 µg of SV40-β-galactosidase reporter gene. The SV40-β-galactosidase vector served as a control for transfection efficiency. Following transfection, the cells were left in serum-free DMEM for 24 h. Luciferase activity was normalized for protein content of the cells and β-galactosidase activity. The data are presented as a percentage of the k1653/j19 CPT-Iα-Luc vector, which was given a relative value of 100 %. All transfections were conducted in duplicate and repeated four to six times and the results are the meanspS.E.
conducted. A DNA probe was created from base pair k383 to j27 and labelled with [γ-$#P]ATP on either the top or bottom strand with T4 polynucleotide kinase. The radiolabelled probe was incubated with proteins isolated from rat liver nuclei. Several regions in the CPT-Iα proximal promoter were protected from DNase I digestion on both the top ( Figure 3A ) and the bottom ( Figure 3B ) strands. Within this region, there are consensus sequences for two Sp1 sites and a CCAAT box. The 5h-most Sp1 site, located between nt k108\k99, and the CCAAT box (k66\k62) were protected from DNase I digestion. The binding of nuclear proteins to the downstream Sp1 site (k28\k21) was not evaluated by DNase I footprinting because this element was too close to the end of the probe. Four additional regions of the promoter were protected by protein binding, and these regions were labelled I to IV. Region I contained protected nt k71\k76 and region II consisted of nt k144\k138 ; region III covered nt k187\k165. Region IV (k215\k244) was strongly protected in the DNase I footprint. The sequences of the protected regions can be seen in Figure 6 . We focused our studies on the Sp1 sites, the CCAAT box element and footprinted regions I-III, contained within the k193\j19 CPT Iα-Luc vector. The deletion of the promoter region from nt k193 to k52 greatly decreased basal expression, suggesting that the factors binding to the sites within this sequence regulate basal transcription. Based on data shown in Figure 2 , the deletion of sequences in the region between nt k320 and k193 did not reduce the basal promoter activity. Therefore no further analysis of footprinted region IV was conducted.
Gel mobility-shift assays were conducted to further characterize the binding of nuclear proteins to elements in the CPT-Iα promoter that were protected by DNase I footprinting. Doublestranded oligonucleotides were generated which corresponded to the two Sp1 sites, the CCAAT box and footprinted regions I-III. Initially, competition studies were conducted with excess of unlabelled probe and rat liver nuclear extract ( Figure 4 ). As shown in Figures 4(A) and 4(B) , oligomers representing sites Sp1(F1) and Sp1(F2) formed one primary complex with the nuclear proteins. This binding activity could be competitively removed by adding an excess of either unlabelled wild-type CPT-Iα Sp1-site oligomer or unlabelled consensus Sp1 oligomer. However, an oligomer representing the cAMP responsive element (CRE) did not compete for binding of the nuclear extract. These observations indicated that Sp proteins specifically bound to these sites. Figure 4 (C) shows that oligomers with mutations in the Sp1(F1) binding site were unable to compete for binding of nuclear proteins. Identical results were seen in a competitionbinding study with a mutant Sp(F2) oligomer (results not shown). Similar experiments were conducted with the CCAAT-box element. The binding of nuclear proteins was competitively prevented by the wild-type CCAAT box oligomer, and excess mutant CCAAT box oligomer was unable to compete for the nuclear protein binding.
In Figures 4(D) and 4(E), gel-shift assays were conducted with oligomers representing regions II and III. One major complex was formed between each of these oligomers and proteins from rat liver nuclei. These studies revealed a specific protein-DNA interaction at each of these sites. To further confirm that the protein interactions at each site were specific, gel-shift probes were generated with 3-4 bp mutations in the protein binding site (described in the Experimental section). An excess of unlabelled oligomers containing the mutated sites was added to the gel-shift competition studies and it was found that the mutant oligomers did not compete for protein binding. Because region III was so broad, two mutant oligonucleotides were generated. Neither mutation was an effective competitor of nuclear protein binding. Similar observations were made with region I (results not shown). We can conclude from these competition experiments that each of the six CPT promoter protein binding sites shows specificity for nuclear protein binding, and that mutations within these sites specifically disrupt protein binding.
To identify specific proteins that bind to various elements in the promoter, supershift studies were conducted by adding specific antibodies to each of the DNA-protein binding reactions. Multiple members of the Sp transcription factor family have been identified [21] . As is shown in Figure 5 (A), addition of either Sp1 antibody or Sp3 antibody was able to form a supershifted complex with the Sp1(F1) oligomer. When both antibodies were added simultaneously, the entire Sp protein binding activity was Nuclear factor Y and Sp1 regulate CPT-Iα gene expression
Figure 3 DNase-I footprint analysis of protein-binding domains in the CPT-Iα proximal promoter
A 400 bp fragment of the CPT-Iα promoter from nt k383 to j19 was 32 P-labelled on the top strand (Top). The CPT-Iα-labelled probe was incubated with proteins isolated from rat liver nuclei (RLNE) and digested with DNase I. Protected regions of the CPT-Iα promoter are indicated on the right with boxes and labelled. Sp1 and NF-Y protein binding sites are indicated, as are the protected regions I, II, III and IV. The G-ladder is shown for the labelled top strand probe. The same CPT-Iα fragment was labelled on the bottom strand and analysed as indicated above.
supershifted. These results indicated that both isoforms were present in rat liver nuclear extract and were able to bind this element. The antibody to Sp4 was not able to form a supershifted complex (results not shown). Similar experiments were conducted with the oligomer representing the element Sp1(F2) ( Figure 5B), and essentially identical results were obtained. Since our transfections were conducted in HepG2 cells, we also tested the binding of nuclear proteins isolated from HepG2 nuclei to the Sp1 sites in the CPT-Iα promoter. The antibodies to Sp1 and Sp3 supershifted the binding activity in HepG2 cell nuclear extract (results not shown). These results indicate that the same proteins were binding to the CPT-Iα Sp1 sites.
The transcription factor NF-Y frequently binds to CCAAT boxes. Therefore we tested the ability of an NF-Y antibody to alter the binding of nuclear proteins to the oligomer representing the CCAAT box in the CPT-Iα gene ( Figure 5C ). The NF-Y antibody supershifted the major protein-DNA complex indicating NF-Y is the major protein binding to this element. The supershift experiments were also performed with HepG2 nuclear extract and similar results, with respect to NF-Y binding, were obtained (results not shown). Based on computer searches for consensus DNA transcription-factor binding elements, footprinted regions I-IV did not appear to contain any homologous sequences. The identity of the proteins that bind these regions has not been determined. The contribution of each specific protein binding site to basal expression of the CPT-Iα gene was determined by site-directed mutagenesis of each site in the context of k1653\j19 CPT-Iα-Luc vector. Each Sp1 site, the NF-Y site, and footprinted regions I, II and III were disrupted individually. The mutations introduced had been shown previously to disrupt the binding of nuclear factors (Figure 4 ). In addition, two double mutants were created, in which both Sp1 sites or the Sp1(F1) and the NF-Y site were mutated. These CPT-Iα-Luc vectors were transiently transfected into HepG2 cells and luciferase assays were performed. Luciferase activity of the mutated protein binding sites was normalized to the wild-type k1653\j19 CPT-Iα-Luc vector ( Figure 6 ).
We observed a significant decrease in basal expression when either the Sp1(F2) site or the NF-Y site was mutated. The relative expression of CPT-Iα-Luc vectors with mutations in the Sp1(F2) site and NF-Y site was 24p6 % and 31p8 % respectively. The disruption of the Sp1(F1) site caused a decrease in expression to 65p4 %. The mutation of regions I, II, and III resulted in vectors that expressed at relative levels of 82p10 %, 63p12 % and 89p4 % respectively. A further decrease in basal activity of the CPT-Iα promoter occurred when both Sp1 sites or Sp1(F1) and NF-Y sites were mutated simultaneously (5p1 % and 16p2 % respectively). These results indicated that Sp1 and NF-Y have a critical role in regulating the basal expression of the CPT-Iα gene. We wished to determine whether Sp1 or Sp3 was responsible for stimulating transcription of CPT-Iα. Sp3 has been reported to have both inhibitory and stimulatory roles [22] . Other studies have found that Sp1 and Sp3 have a synergistic effect on the trans-activation of various genes [23] [24] [25] . The k1653\j19 CPT-Iα-Luc vector used in the present study was co-transfected with mammalian expression vectors for Sp1 and Sp3 [21] , but overexpression of either protein did not alter transcription of the CPT-Iα gene (results not shown). It is likely that both proteins stimulate transcription of the CPT-Iα gene and are present in great abundance in HepG2 cells.
Sp1 has an important role in directing transcription from TATA-less genes. Sp1 assists in the recruitment of TATA factors and other transcriptional initiation factors to the promoter [26, 27] . In the promoters of rat growth hormone and human placental lactogen B genes, Sp1 contributes to both basal transcriptional activity and to thyroid hormone responsiveness [28, 29] . The ratio of Sp1 protein to activator protein (AP)-2 is involved in the developmental regulation of K3 keratin gene transcription [30] . An interaction between Sp1 and the CCAATenhancer binding protein (C\EBP) β has been reported to regulate basal gene expression in a rat liver CYP450 gene [31] . NF-Y is present in the promoters of many TATA-less genes and may have a similar role to Sp1 [26, 32] . NF-Y enhances the thyroid hormone responsiveness of the S14 gene through functional interaction with the thyroid hormone receptor [33] . Additionally, NF-Y and Sp1 co-operate to regulate transcription of the rat fatty acid synthase gene through a physical interaction [34] . The various functions attributed to NF-Y and Sp1 suggest that these factors may participate in the developmental and hormonal aspects of CPT-Iα transcriptional regulation as well as basal gene expression.
At birth, the expression of CPT-Iα is increased five-fold in the liver [7] . C\EBP α induces the expression of several genes encoding metabolic enzymes, such as phosphoenolpyruvate carboxykinase and glycogen synthase in the liver at birth [35, 36] . We co-transfected our CPT-Iα-Luciferase vectors with a dominant negative C\EBP vector called A-C\EBP [37] . This vector did not decrease the expression of CPT-Iα-Luc suggesting that C\EBP proteins do not regulate CPT-Iα expression (results not shown). Other factors must be involved in the induction of this gene at birth. Glucocorticoids are additionally responsible for inducing phosphoenolpyruvate carboxykinase and tyrosine aminotransferase at birth [38] . However, dexamethasone had only a small effect on CPT-Iα transcription (results not shown).
The proximal promoter of the CPT-Iα gene is similar to the promoters of other acyl transferases and enzymes involved in fatty acid oxidation. The medium-chain acyl-CoA dehydrogenase promoter is TATA-less with Sp1 playing a prominent role in basal expression [39] . The liver carnitine octanoyltransferase (peroxisomal CPT) gene does not have a TATA element, but contains CCAAT motifs and GC boxes for Sp1 binding [40] . The promoter of CPT-Iβ has been cloned from several species. Human CPT-Iβ utilizes two start sites of transcription yielding alternative exons, while the rat CPT-Iβ gene has a single first exon. [11, 20, 41] . In both cases, the promoters are TATA-less. CPT-Iβ is expressed only in skeletal muscle, cardiac myocytes and adipose tissue whereas CPT-Iα is expressed in a variety of other tissues [1, 2] . Our studies did not identify any sequences that might be involved in the tissue-specific regulation of the CPT-Iα gene. Our CPT-Iα-Luc vectors were well expressed in the L6 muscle cell line (results not shown). In summary, we have characterized the proximal CPT-Iα promoter and identified elements that regulate basal gene expression. Sp1, Sp3 and NF-Y bound to the proximal promoter and played a major role in driving basal expression of this gene.
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